Kardio-Med Silesia

What Kardio-Med Silesia does

Kardio-Med Silesia (full legal name: Śląski Park Technologii Medycznych Kardio-Med Silesia Sp. z o.o.) is a privately held Polish medical research and technology center headquartered in Zabrze, Silesian Voivodeship. The company describes itself as a "modern research and implementation center meeting the highest European standards" and operates an integrated multi-laboratory infrastructure built around cardiac research, biotechnology, medical-device evaluation, and clinical services.

Its core assets are eight specialized units: a multi-specialty laboratory (cellular, stem-cell, histology, biocompatibility), a 3D bioprinting and 3D printing laboratory (biodegradable corneal reconstruction scaffolds with limbal cells), an isolated heart laboratory (ex vivo cardiac research), a liposome laboratory (drug delivery, RNA-based therapeutics including personalized AML therapy), a COVID-19 BSL-2 laboratory, a genomics laboratory, and small- and large-animal facilities (capacity for ~4,500 mice, 280 rats, minipigs and pigs with surgical suite including angiography, OCT, anesthesia and extracorporeal circulation). The cluster is wrapped by a medical telemonitoring center for ICD/CRT-D patients, specialist outpatient clinics running clinical trials, and a training program for physicians.

The company is monetized through a hybrid of public grants (Polish Medical Research Agency, National Science Centre, NCBR, Ministry of Health, Regional Programme of Silesian Voivodeship, Horizon 2020), contract research and GLP/ISO 10993 biological evaluation of medical devices (quote-based pricing, undisclosed), clinical trial services, telemonitoring under Polish healthcare reimbursement, and fee-based medical training. Customer segments are healthcare providers and hospitals, medical device and pharmaceutical companies requiring preclinical testing, and medical professionals receiving continuing education. Strategic co-development partners include Śląskie Centrum Chorób Serca in Zabrze, Śląski Uniwersytet Medyczny, and Centrum Onkologii w Gliwice, with operational synergy derived from co-location in the Zabrze cardiology cluster.

Name

Kardio-Med Silesia

Legal name

Śląski Park Technologii Medycznych Kardio-Med Silesia Sp. z o.o.

Website

https://kmptm.pl

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Kardio-Med Silesia is a privately held Polish medical research center in Zabrze operating GLP-certified, ISO 10993-compliant laboratories for preclinical, in vitro/in vivo, and 3D bioprinting research, serving medical device companies, hospitals, and clinical trial sponsors in the Silesian region.

Ownership category

akta.pro rank

Product category

Preclinical Medical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Surgical and Medical Instrument Manufacturing (339112)

SIC

Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

akta.pro secondary industries

General Cardiology (Consultative) (HLAKABAA), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Preclinical medical research
• Biological evaluation services
• Clinical trial services
• 3D bioprinting research
• Medical telemonitoring

Headquarters

HQ city

Zabrze

HQ country

Poland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales

Distribution channels1 record

Marketing channels5 records

Core offering

Kardio-Med Silesia is a GLP-certified research and implementation center conducting in vitro, in vivo, and clinical medical research. The company provides ISO 10993 biological evaluation of medical devices, 3D bioprinting and tissue engineering, liposome-based drug delivery research, stem cell (iPSC) studies, and remote cardiac telemonitoring, serving medical device manufacturers, pharmaceutical companies, and healthcare providers.

Product overview

Kardio-Med Silesia (Śląski Park Technologii Medycznych) is a modern research and implementation center in Zabrze, Poland, established in 2015. The organization operates as a multi-laboratory complex offering biological evaluation of medical devices (in vitro, in vivo studies under GLP standards per ISO 10993), clinical research services, and specialized healthcare services. The core infrastructure includes the Laboratorium Wielospecjalistyczne (conducting cellular, stem cell, and genomics research), Laboratorium biodruku i druku 3D (for corneal reconstruction and tissue engineering), Laboratorium liposomowe (for RNA-based therapeutics and drug delivery), and specialized animal facilities for small and large animals. The center provides medical telemonitoring services through its Centrum Telemonitoringu Medycznego, operates outpatient specialist clinics conducting clinical trials, and offers professional training programs. Current major projects include a personalized liposomal therapy for AML, an anti-COVID drug, and biodegradable corneal reconstruction using 3D bioprinting. The center collaborates closely with Śląskie Centrum Chorób Serca and Śląski Uniwersytet Medyczny.

Differentiator

Problem solved

Functional benefit

Products and services

• Biological Evaluation of Medical Devices (GLP / ISO 10993) Preclinical in vitro and in vivo biological safety testing of medical devices compliant with ISO 10993 under Good Laboratory Practice, offered to medical device manufacturers requiring regulatory-grade biocompatibility data.
• Clinical Trials Clinical study design, coordination, and execution services for medical device and pharmaceutical sponsors, leveraging on-site specialist outpatient clinics and cardiology, neurology, and vascular medicine expertise.
• Medical Telemonitoring Center Remote telemonitoring service for cardiac patients, including implanted device (pacemaker, ICD, CRT) data review and clinical surveillance, delivered to healthcare providers and patients under cardiology supervision.
• Specialist Outpatient Clinics Specialist outpatient medical consultations in cardiology, neurology, angiology, vascular medicine, and cardiac surgery, serving patients referred for advanced diagnostics and treatment.
• Medical Laboratory Diagnostics Diagnostic laboratory services including hematology, biochemistry, immunology, microbiology, genetic and molecular testing, with specialized assays such as non-invasive endometriosis blood-based diagnostics for referring physicians and patients.
• Medical Training Programs Structured training programs and courses for physicians, researchers, and medical professionals covering cardiology, cardiac surgery, biotechnology, and laboratory techniques.
• Research Projects and Studies Contract and collaborative applied research projects in 3D bioprinting, tissue engineering, liposome-based drug delivery, stem cell (iPSC) biology, genomics, and isolated heart / extracorporeal circulation studies, delivered to industry and academic partners.
• Innovation Center Services

Quantifiable outcome

• Near 200,000 patients examined through various diagnostic and screening programs
• +4 more outcomes

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Eight partnerships are on record, tiered core, major and supporting.

• Śląskie Centrum Chorób Serca w Zabrzu (Silesian Center for Heart Disease in Zabrze)coreStrategic or Co-development PartnerClose collaboration since establishment in 2015. The Heart Disease Center and Kardio-Med Silesia operate synergistically within the same medical campus, enabling joint research projects and shared expertise in cardiology research and treatment development.
• Śląski Uniwersytet Medyczny (Medical University of Silesia)coreStrategic or Co-development PartnerAcademic partnership providing research collaboration, access to medical expertise, and integration with medical education programs. Joint projects include stem cell research and cardiac disease studies.
• Centrum Onkologii w Gliwicach (Oncology Center in Gliwice)coreStrategic or Co-development PartnerCollaboration in oncology research including cancer studies and development of novel therapeutic approaches.
• Fundacja Śląskiego Centrum Chorób Serca (Foundation of the Silesian Center for Heart Disease)majorStrategic or Co-development PartnerFoundation partnership supporting cardiac research initiatives and technology development in cardiology.
• Fundacja Rozwoju Kardiochirurgii (Foundation for the Development of Cardiosurgery)majorStrategic or Co-development PartnerPartnership supporting the development of cardiosurgical techniques and related research activities.
• Startup City ZabrzesupportingGTM or Marketing PartnerPartnership supporting startup ecosystem development in the Zabrze region, connecting innovative healthcare technology ventures.
• Urteste S.A.supportingStrategic or Co-development PartnerCollaboration in cancer screening research - healthy volunteer recruitment for early cancer detection experimental studies conducted by Polish scientists.
• Urząd Skarbowy (Tax Office)supportingOthersGovernment entity for tax compliance and financial regulatory oversight.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Labcorp Drug Development (now Fortrea): Large CRO providing central labs, preclinical, and clinical trial services; comparable to Kardio-Med Silesia's integrated clinical-research and laboratory offerings.
• SGS SA: Global testing, inspection and certification company with life-sciences and medical-device testing services; comparable to Kardio-Med Silesia's GLP-certified testing and compliance offering.
• Medtronic: Global cardiac device leader with remote monitoring for ICDs (CareLink); comparable for the telemonitoring franchise, though Kardio-Med operates as the monitoring service provider rather than device maker.
• Eurofins Scientific: International testing services group with strong GLP and medical-device testing capabilities across Europe; directly overlaps with Kardio-Med Silesia's biological evaluation of medical devices and clinical diagnostics offerings.
• Biosense Webster (Johnson & Johnson): Cardiac ablation and electrophysiology business with clinical training programs; comparable to Kardio-Med Silesia's electrophysiology training offerings (e.g., 3D ablation courses) to physicians.
• Charles River Laboratories: Global CRO offering preclinical safety, biological evaluation, and laboratory services; comparable to Kardio-Med Silesia's GLP/ISO 10993 medical-device testing and animal model work, but at vastly larger scale and global reach.

Direct peers

• BIOTRONIK: Cardiac device company with home monitoring (BIOTRONIK Home Monitoring) for ICD/CRT-D patients; directly comparable to Kardio-Med Silesia's Centrum Telemonitoringu Medycznego for implantable cardiac devices.

Regional players

• OncoArendi Therapeutics: Polish biotech developing innovative small-molecule therapeutics; comparable as a Poland-based life-sciences R&D organization leveraging EU and national research funding, similar to Kardio-Med Silesia.
• Celon Pharma: Polish biopharmaceutical company developing specialty therapeutics including oncology; comparable to Kardio-Med Silesia as a Polish R&D entity, with overlap on RNA-based and liposomal therapeutic directions.

Emerging players

• Urteste S.A. Polish cancer-diagnostic startup collaborating with Kardio-Med Silesia on healthy-volunteer screening studies; relevant peer given active R&D partnership and overlap in clinical/diagnostic research infrastructure.

Market position

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/KardioMedSilesia
• LinkedInlinkedin.com/company/-l-ski-park-technologii-medycznych-kardio-med-silesia

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kardio-Med Silesia